ANDA 203925, held by Sun Pharm. Risedronate Sodium.
As of Nov 16, 2026, ANDA 203925 (Risedronate Sodium), held by Sun Pharm, was first approved by FDA on Jul 9, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Risedronate Sodium35MG · tablet, delayed release;oral | Risedronate Sodium | Discontinued |
| Dec 18, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 9, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters